Drug intelligence / Profile preview

BRII-297

Development stage: Phase 1
Lead developer: Brii Biosciences
Modality: Small Molecules
Administration: Parenteral, Intramuscular

Overview

BRII-297 is a novel small molecule drug under development by Brii Biosciences for the treatment of major depressive disorder, anxiety disorders, and postpartum depression. It is designed as a long-acting injectable therapeutic candidate and acts as a positive allosteric modulator of the Gamma-aminobutyric acid A receptor (GABA(A)). The drug is administered via parenteral or intramuscular injection and is currently in Phase 1 clinical trials for postpartum depression and anxiety disorders. Its mechanism of action involves enhancing GABAergic neurotransmission through modulation of the GABA(A) receptor, which plays a key role in regulating mood and anxiety[1][2][4].

Targets

GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on BRII-297.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRII-297.

Explore the full profile